← Eichor
Study identifier: NCT06900062 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping

Condition: Bronchiectasis Adult  ·  Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

PhaseN/A
Planned participants1500
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

Bronchiectasis is a heterogeneous airway disease with diverse causes, making precise diagnosis, prognosis, and treatment response prediction challenging. Identifying patient subgroups (phenotypes) and molecular profiles (endotypes) can enhance individualized assessment and management. While prior studies, primarily in European populations, have identified key phenotypes and endotypes, their relevance to Chinese patients remains unclear due to geographic and clinical differences. Specific causes of bronchiectasis, such as allergic bronchopulmonary aspergillosis (ABPA) and primary ciliary dyskinesia (PCD), may also exhibit distinct pathophysiology requiring further exploration. The C-BRIDGE Study seeks to characterize phenotypes and endotypes in Chinese bronchiectasis patients during stable disease and exacerbations, evaluate differences in clinical outcomes across these subgroups, and develop personalized medicine strategies based on these findings, applicable in China and globally. Primary Objective: To identify molecular endotypes of bronchiectasis that accurately predict prognosis and guide treatment responses. Secondary Objectives: To characterize molecular endotypes of stable bronchiectasis in Chinese patients. To define molecular endotypes of bronchiectasis exacerbations in Chinese patients. To investigate molecular endotypes specific to allergic bronchopulmonary aspergillosis (ABPA). To explore genotypes and inflammatory endotypes of cystic fibrosis (CF) and prima…

This description comes directly from the study's public registry record.

Talk to the study team

Yong-hua Gao, Ph.D.  ·  +86 17321278520  ·  gaoyonghuahust@163.com

Always discuss trial participation with your own doctor first.

Locations (9)

Lin LiuGuiyang, Guizhou, ChinaRecruiting
Lei SongChangchun, Jilin, ChinaRecruiting
Qian QiJinan, Shangdong, ChinaRecruiting
He-feng ChenShanghai, Shanghai Municipality, ChinaRecruiting
Zhou-fang MeiShanghai, Shanghai Municipality, ChinaRecruiting
Jun SheShanghai, Shanghai Municipality, ChinaRecruiting
Xue-ling WuShanghai, Shanghai Municipality, ChinaRecruiting
Yong-hua GaoShanghai, Shanghai Municipality, ChinaRecruiting
Xiao-long MaJiaxing, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06900062